American Century Companies Inc. Makes New $857,000 Investment in LeMaitre Vascular, Inc. $LMAT

Key Points

• American Century Companies Inc. has acquired over 10,000 shares of LeMaitre Vascular, Inc. during the first quarter, valued at approximately $857,000.
• LeMaitre Vascular reported earnings of $0.60 per share for the last quarter, exceeding analysts' expectations and demonstrating a 15% year-over-year revenue growth.
• The company declared a quarterly dividend of $0.20 per share, resulting in an annualized yield of 0.8% with a payout ratio of 38.83%.

American Century Companies Inc. purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,214 shares of the medical instruments supplier's stock, valued at approximately $857,000.

A number of other hedge funds also recently made changes to their positions in LMAT. Opal Wealth Advisors LLC bought a new stake in LeMaitre Vascular in the first quarter valued at approximately $26,000. NBC Securities Inc. acquired a new position in LeMaitre Vascular in the first quarter valued at $36,000. US Bancorp DE boosted its position in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 368 shares during the last quarter. Blueshift Asset Management LLC acquired a new stake in LeMaitre Vascular during the 1st quarter worth about $232,000. Finally, Cetera Investment Advisers raised its position in shares of LeMaitre Vascular by 11.5% in the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock worth $254,000 after acquiring an additional 284 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on LMAT. Cantor Fitzgerald raised their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $97.60.

LeMaitre Vascular Stock Down 1.2%

NASDAQ LMAT traded down $1.19 during trading hours on Wednesday, hitting $94.43. The company's stock had a trading volume of 6,681 shares, compared to its average volume of 187,895. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The company's 50-day simple moving average is $89.16 and its two-hundred day simple moving average is $86.15. The company has a market capitalization of $2.14 billion, a PE ratio of 46.10, a price-to-earnings-growth ratio of 2.50 and a beta of 0.79. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.LeMaitre Vascular's quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 over the last 90 days. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.